Indication · Sjögren's Disease

Sjögren's Disease FDA approvals, PDUFA dates and pipeline.

Updated Snapshot 20261116T222116ZBuilt

We track 4 Sjögren's Disease drugs. No FDA approvals recorded yet.

Drugs

DrugSponsorModalityDesignations
DDY391NVS——
efgartigimod ph20 sc (PH20)ARGX——
MRT-6160GLUE——
vay736 1ml pfs (VAY736)NVS——

Upcoming catalysts

DateDrugCompanyEventIndicationStatusSource
Feb to May 2029Quarter disclosedDDY391NVSTopline readoutSjögren's DiseaseScheduledClinicalTrials.gov
February 2029Month disclosedDDY391NVSPrimary completionSjögren's DiseaseScheduledClinicalTrials.gov

Past catalysts and decisions

DateDrugCompanyEventIndicationStatusSource
September 8, 2026MRT-6160GLUETrial startSjögren's diseaseCompletedSEC 8-K Exhibit 99.1

All indications · Approval rates by indication

Questions

What Sjögren's Disease drugs have upcoming PDUFA dates?

None disclosed.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.